BR112015020443A2 - desamorfização de formulações secadas por atomização via mistura por atomização - Google Patents

desamorfização de formulações secadas por atomização via mistura por atomização

Info

Publication number
BR112015020443A2
BR112015020443A2 BR112015020443A BR112015020443A BR112015020443A2 BR 112015020443 A2 BR112015020443 A2 BR 112015020443A2 BR 112015020443 A BR112015020443 A BR 112015020443A BR 112015020443 A BR112015020443 A BR 112015020443A BR 112015020443 A2 BR112015020443 A2 BR 112015020443A2
Authority
BR
Brazil
Prior art keywords
spray
spray dried
dried powder
active ingredient
demorphization
Prior art date
Application number
BR112015020443A
Other languages
English (en)
Other versions
BR112015020443A8 (pt
Inventor
Miller Danforth
Huang Daniel
Weers Jeffry
Tarara Thomas
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50391236&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112015020443(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112015020443A2 publication Critical patent/BR112015020443A2/pt
Publication of BR112015020443A8 publication Critical patent/BR112015020443A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

resumo patente de invenção: "desamorfização de formulações secadas por atomização via mistura por atomização". a presente invenção refere-se a formulações de pó seco para inalação e seu uso no tratamento de doenças e condições. a formulação contém uma mistura uniforme de um primeiro pó secado por atomização e um segundo pó secado por atomização. o primeiro pó secado por atomização contém partículas secadas por atomização de um ingrediente terapeuticamente ativo disperso num excipiente hidrofóbico farmaceuticamente aceitável. o segundo pó secado por atomização contém partículas secadas por atomização formadas a partir de um excipiente hidrófobo farmaceuticamente aceitável, mas são substancialmente livres de qualquer ingrediente terapeuticamente ativo. o ingrediente ativo no primeiro pó secado por atomização é carregado sob carga suficientemente elevada para compensar o segundo pó secado por atomização que é substancialmente isento de qualquer ingrediente ativo. um processo para a preparação de tais formulações é também descrito.
BR112015020443A 2013-03-14 2014-03-11 formulação em pó para inalação, seus usos e seu processo de preparação, e composição farmacêutica BR112015020443A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361784865P 2013-03-14 2013-03-14
PCT/IB2014/059632 WO2014141069A1 (en) 2013-03-14 2014-03-11 Deamorphization of spray-dried formulations via spray-blending

Publications (2)

Publication Number Publication Date
BR112015020443A2 true BR112015020443A2 (pt) 2017-07-18
BR112015020443A8 BR112015020443A8 (pt) 2019-11-12

Family

ID=50391236

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015020443A BR112015020443A8 (pt) 2013-03-14 2014-03-11 formulação em pó para inalação, seus usos e seu processo de preparação, e composição farmacêutica

Country Status (11)

Country Link
US (1) US20150374623A1 (pt)
EP (1) EP2968110A1 (pt)
JP (1) JP6232079B2 (pt)
KR (1) KR102074543B1 (pt)
CN (1) CN105209013B (pt)
AU (1) AU2014229361B2 (pt)
BR (1) BR112015020443A8 (pt)
CA (1) CA2898700C (pt)
MX (1) MX2015012529A (pt)
RU (1) RU2698331C2 (pt)
WO (1) WO2014141069A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016142708A2 (en) 2015-03-10 2016-09-15 Cipla Limited Pharmaceutical composition
KR20220019027A (ko) 2019-06-10 2022-02-15 레스피라 테라퓨틱스 인크. 담체-기반 제제 및 관련 방법
KR102669919B1 (ko) * 2019-07-10 2024-05-28 한미약품 주식회사 흡입용 캡슐제 및 이의 제조방법
KR102330428B1 (ko) * 2019-10-14 2021-11-24 한미약품 주식회사 흡입 제형용 건조 분말 및 이의 제조방법
CN114344285B (zh) * 2020-10-14 2023-11-14 江苏恒瑞医药股份有限公司 改良的可吸入团聚物

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956062A (en) 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
IT1016489B (it) 1974-03-18 1977-05-30 Isf Spa Inalatore
DE3260474D1 (en) 1981-02-02 1984-09-06 Schering Corp Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them
US6536427B2 (en) 1990-03-02 2003-03-25 Glaxo Group Limited Inhalation device
WO1993000123A1 (en) 1991-06-26 1993-01-07 Schering Corporation Inhalation device for powdered medicaments
JP2924924B2 (ja) 1992-12-18 1999-07-26 シェリング・コーポレーション 粉末薬物のための吸入器
US5837699A (en) 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
NZ293163A (en) 1994-09-21 1998-09-24 Inhale Therapeutic Syst Inhalation medicament disperser, aerosol from high pressure gas entrainment of fluidised powder drawn from receptacle feed tube
WO1997025086A2 (en) 1996-01-03 1997-07-17 Glaxo Group Limited Inhalation device
HU221033B1 (hu) 1996-02-21 2002-07-29 Schering Corp. Poradagoló készülék
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US6613795B2 (en) 1996-11-11 2003-09-02 Christian Noe Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments
JP2001504459A (ja) 1996-11-11 2001-04-03 ノエ・クリスティアン・エル 対掌体純粋な、塩基性アリール―シクロアルキル―ヒドロキシカルボン酸エステル、その製造方法及びこれを薬剤に使用する方法
US6010935A (en) 1997-08-21 2000-01-04 Micron Technology, Inc. Self aligned contacts
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
UA73924C2 (en) 1998-10-09 2005-10-17 Nektar Therapeutics Device for delivering active agent formulation to lungs of human patient
GB9913083D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
JP4377076B2 (ja) 1999-05-28 2009-12-02 ネクター セラピューティクス 噴霧化された薬物の計量された量を投与する装置と方法
US6858199B1 (en) * 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
US20010029947A1 (en) 1999-12-17 2001-10-18 Steve Paboojian Receptacles to facilitate the extraction of powders
US7069929B2 (en) 2000-02-01 2006-07-04 Quadrant Technologies Limited Dry powder inhaler
MXPA02001323A (es) 2000-05-10 2004-07-16 Alliance Pharma Microgranulos con base fosfolipida para la liberacion de farmaco.
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
EP1992335A1 (en) * 2001-11-01 2008-11-19 Nektar Therapeutics Spray drying methods and compositions thereof
EP1486204A1 (en) * 2002-03-18 2004-12-15 Yamanouchi Pharmaceutical Co. Ltd. Powdery medicinal compositions for inhalation and process for producing the same
ES2718455T3 (es) * 2002-03-20 2019-07-02 Civitas Therapeutics Inc Formulaciones terapéuticas sostenidas inhalables
US20040060265A1 (en) 2002-06-27 2004-04-01 Nektar Therapeutics Controlling the flow of a powder
MXPA05010842A (es) 2003-04-09 2006-03-30 Nektar Therapeutics Aparato de nebulizacion con protector de entrada de aire.
GB0317374D0 (en) 2003-07-24 2003-08-27 Glaxo Group Ltd Medicament dispenser
GB2407042B (en) 2003-10-17 2007-10-24 Vectura Ltd Inhaler
BRPI0507884A (pt) 2004-02-24 2007-08-07 Microdose Technologies Inc método e equipamento para administração de medicamento com base em jato sintético
GB0410712D0 (en) 2004-05-13 2004-06-16 Novartis Ag Organic compounds
GB0413960D0 (en) 2004-06-22 2004-07-28 Novartis Ag Organic compounds
BRPI0707991B8 (pt) * 2006-02-22 2021-05-25 Mannkind Corp métodos de preparação de um medicamento em pó seco com uma propriedade farmacêutica melhorada, dito pó seco e uso de uma quantidade efetiva do pó seco
US8198450B2 (en) 2006-06-30 2012-06-12 Novartis Ag Quinolinone derivatives and their pharmaceutical compositions
EP2668970B1 (en) 2006-10-25 2016-07-06 Novartis AG Powder dispersion apparatus
LT2435025T (lt) * 2009-05-29 2016-09-26 Pearl Therapeutics, Inc. Veikliosios medžiagos tiekimas per kvėpavimo takus
JOP20120023B1 (ar) * 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية

Also Published As

Publication number Publication date
KR20150119087A (ko) 2015-10-23
RU2015143927A (ru) 2017-04-20
MX2015012529A (es) 2016-07-05
US20150374623A1 (en) 2015-12-31
JP2016512224A (ja) 2016-04-25
WO2014141069A1 (en) 2014-09-18
CN105209013A (zh) 2015-12-30
AU2014229361A1 (en) 2015-08-13
CN105209013B (zh) 2019-04-26
CA2898700A1 (en) 2014-09-18
KR102074543B1 (ko) 2020-02-06
RU2698331C2 (ru) 2019-08-26
EP2968110A1 (en) 2016-01-20
JP6232079B2 (ja) 2017-11-15
BR112015020443A8 (pt) 2019-11-12
AU2014229361B2 (en) 2016-08-04
CA2898700C (en) 2022-07-19

Similar Documents

Publication Publication Date Title
BR112015021814A2 (pt) aglomerados respiráveis de partículas carreadoras porosas e fármaco micronizado
BR112013019540A2 (pt) formulações de pó seco de partículas que contêm dois ou mais ingredientes ativos para o tratamento de doenças obstrutivas ou inflamatórias das vias aéreas
BR112015020443A2 (pt) desamorfização de formulações secadas por atomização via mistura por atomização
CL2016000735A1 (es) Inhalador de polvo seco que comprende una composición farmacéutica inhalable que comprende propionato de fluticasona, xinafoato de salmeterol y un vehículo de lactosa; uso para tratar asma o epoc.
AR082443A1 (es) Formulacion de polvo seco que comprende un inhibidor de fosfodiesterasa
BRPI0606332A2 (pt) composição farmacêutica de bendamustina, preparação liofilizada, forma de dosagem farmacêutica, método para obter aprovação oficial para um produto de bendamustina, processo para fabricar uma preparação liofilizada de bendamustina, solução ou dispersão de pré-liofilização de bendamustina, pó liofilizado, método para preparar uma preparação liofilizada de bendamustina, formulação para liofilização, e, uso de uma solução farmaceuticamente aceitável
CL2012002497A1 (es) Compuestos derivados de imidazopirimidina,sustituidos, inhibidores de la pde10a; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento o prevencion de trastornos psicoticos, esquizofrenia, enfermedad de parkinson, esclerosis multiple, entre otras.
CO6640319A2 (es) Formulación en polvo seca que comprende una droga antimuscarínica
CY1120530T1 (el) Απο του στοματος χορηγησιμη φαρμακευτικη συνθεση
PH12020500543A1 (en) Nonracemic mixtures and uses thereof
MY175781A (en) Composition comprising at least two dry powders obtained by spray drying to increase the stability of the formulation
BR112015019412A8 (pt) inibidores de bace1, seus usos, e composição farmacêutica
PE20141703A1 (es) Formulacion seca en polvo que comprende un corticoesteroide y un beta-adrenergico para administrar por inhalacion
CL2018003178A1 (es) Composición farmacéutica
BR112015027017A2 (pt) composições farmacêuticas inaláveis e dispositivos inaladores que contêm as mesmas
EA201492097A1 (ru) 5-амино[1,4]тиазины в качестве ингибиторов бета-секретазы 1
BR112014016472A8 (pt) formulação farmacêutica estável para administração oral que compreende levocetirizina ou um sal farmaceuticamente aceitável da mesma e montelukast ou um sal farmaceuticamente aceitável do mesmo
BR112014031706A8 (pt) Composições farmacêuticas orais, e composição farmacêutica oral compreendendo itraconazol
MX2017004476A (es) Composicion que comprende al menos un polvo seco obtenido por secado por atomizacion para aumentar la estabilidad de la formulacion.
BR112015021525A2 (pt) composições farmacêuticas secas compreendendo nanopartículas de agente ativo ligadas a partículas de tansportadores
BR112017021111A2 (pt) processo para fabricação de misturas de pós secos
ES2524865T1 (es) Composiciones farmacéuticas estables en forma de comprimidos de liberación inmediata
WO2013168179A3 (en) Controlled release pharmaceutical formulations of antiviral agents
TR201905033A2 (tr) Palmi̇toi̇letanolami̇d i̇çeren stabi̇l formülasyonlar
AR109186A1 (es) Procedimiento de estabilización de tamaño de partícula de bromuro de glicopirronio

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time